Table 3.
Comparison with other contemporaneous studies
| Reference | Approach | Study time period | No. of patients | MAC (%) | Related or unrelated allografts | % AML, MDS, or ALL patients | Median follow-up, y | GVHD CI (%) | NRM CI (%) | Relapse CI (%) | DFS (%) | OS (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute grade II-IV at 100 d | Acute grade III-IV, at 100 d | Chronic at 2 y | At 1 y | At 3 y | At 2 y (AML in CR only) | At 3 y (AML in CR only) | At 3 y | At 2 y | At 3 y (AML in CR only) | At 3 y | At 2 y | At 3 y | ||||||||
| This study | PTCy | 2004-2011 | 209 | 100 | Both | 100 | 4.0 | 45 | 11 | 13 | 15 | 17 | 26 | 30 | 36 | 53 | 48 | 46 | 61 | 58 |
| 6* | CNI/ MTX | 2004-2009 | 278 | 80 | Unrelated | 87 | 3.0 | 46 | 14 | 41 | 23 | 27 | NR | NR | 30 | 44 | NR | 43 | 49 | 46 |
| 7† | ATG-F/ CsA/MTX | 2003-2007 | 103 | 100 | Unrelated | 94 | 3.0 | 33 | 12 | 30 | NR | 19 | NR | NR | 33 | NR | NR | NR | NR | 55 |
| 7† | CsA/MTX | 2003-2007 | 98 | 100 | Unrelated | 86 | 3.0 | 51 | 25 | 60 | NR | 34 | NR | NR | 28 | NR | NR | NR | NR | 43 |
| 35 | TCD‡ | 2005-2008 | 44 | 100 | Related | 100 AML CR1/2 | 2.8 | 23 | 4.5 | 19 | NR | 21 (2 y) | 24 | NR | NR | 55 | NR | NR | 59 | NR |
| 35 | CNI-based§ | 2003-2006 | 84 | 100 | Related | 100 AML CR1/2 | 4.0 | 39 | 9.5 | 50 | NR | 19 (2 y) | 27 | NR | NR | 54 | NR | NR | 65 | NR |
| 52 | TCD|| | 2001-2010 | 115 | 100 | Both | 100 AML CR1 | 2.7 | 5 | 1 | 13 | 18 | 24 | NR | 18 | NR | NR | 58 | NR | NR | 57 |
| 52 | Tacro/ mini-MTX¶ | 2001-2010 | 181 | 100 | Both | 100 AML CR1 | 2.4 | 18 | 3 | 53 | 13 | 16 | NR | 25 | NR | NR | 60 | NR | NR | 66 |
ATG, antithymocyte globulin; ATG-F, antithymocyte globulin-Fresenius; CI, cumulative incidence; CsA, cyclosporine-A; MTX, methotrexate; NR, not reported; tacro, tacrolimus.
Data are shown for patients receiving bone marrow allografts. Data were obtained from the original publication and personal communication with the study statistician, Brent Logan (Medical College of Wisconsin). Ninety percent of patients received a CNI and MTX; for the other 10%, treatment was not specified.
Results for early posttransplantation outcomes are taken from Finke et al.53
TCD was performed both ex vivo (Miltenyi CliniMACS CD34 selection) and in vivo (rabbit ATG on day −4).
Included patients received tacrolimus and MTX (n = 39); tacrolimus and mycophenolate mofetil (n = 4); tacrolimus and corticosteroids (n = 1); tacrolimus, MTX, and mycophenolate mofetil (n = 1); or tacrolimus alone (n = 3).
TCD was performed ex vivo, but 45% of patients also received ATG.
Forty-three percent of patients also received ATG, and 8% also received pentostatin.